class of drug have revealed contrasting figures: 7% treatment failure in American tegumentary leishmaniasis (ATL) in Bolivia [4] , 16% in Brazil [5] , 23 .9% in Peru (G. Tulliano, F.C., and A.L.-C., data not shown), and up to 39% in Colombia [6] .
Treatment failure is a complex phenomenon with a potentially multifactorial origin. This may involve (1) host factors, such as genetics, immunological response [7] , characteristics of the patients [6] , and clinical presentation [8] ; (2) treatment features, such as drug quality [9] , duration of therapy, and compliance; and (3) parasite characteristics, such as intrinsic insensitivity (species) [10] and drug resistance [11] . With respect to the specific contribution of parasite drug resistance, reports have been inconsistent. A correlation between resistance to pentavalent antimony (SbV) and treatment outcome has been demonstrated in Leishmania (Leishmania) donovani in India [11] but not in Sudan [12] . In neotropical Leishmania species, a correlation between in vitro susceptibility and clinical phenotypes was observed in patients infected with L. (Viannia) braziliensis or L. (V.) panamensis [13] . However, in that study, parasite susceptibility was determined using promastigotes (vector and culture stage), which are known to be intrinsically insensitive to pharmacological concentrations of SbV [14] . Very recently, a study that focused on L. (V.) panamensis suggested that SbV resistance defined using intracellular amastigotes (the vertebrate stage) could contribute to 40% of treatment failure [15] . However, in that study, isolates from patients who responded to treatment were not included; hence, the predictive value of intrinsic parasite drug resistance could not be completely assessed.
The present article is a part of a multidisciplinary, prospective study aiming at a global understanding of antimony failure (see http://www.leishnatdrug.org). We have characterized the in vitro susceptibility to antimony of clinical isolates from Peruvian patients with ATL who were treated with sodium stibogluconate and who had different treatment outcomes. In total, 37 isolates belonging to 5 different species endemic in Peru were included, and particular attention was given to the most pathogenic species, L. (V.) braziliensis. We tested the susceptibility of intracellular amastigotes to SbV, which is considered to be a prodrug [14] , and to trivalent antimony (SbIII), the reduced, active form of the drug (evidence for the role of SbIII in intracellular amastigote killing has been reviewed elsewhere [14] ). We then compared these in vitro data to the treatment outcome of patients from whom parasites were isolated. We are aware that parasite tolerance to antimonies could originate from exposure to drug or could constitute an intrinsic unresponsiveness. However, because there is no clear answer to this question at this stage (for parasites of subgenus Viannia), and to be consistent with the recent literature on that subject, we have a priori used the term "resistance" throughout the present article.
PATIENTS, MATERIALS, AND METHODS
Patients and clinical protocol. Patients with clinical suspected cutaneous (CL), mucosal (ML), or mucocutaneous (MCL) leishmaniasis were investigated at the Instituto de Medicina Tropical "Alexander von Humboldt," Lima, Peru. Infection with Leishmania species was confirmed by direct examination of punchbiopsy samples, parasite culture, or polymerase chain reaction (PCR) [16] . Between November 2001 and December 2004, patients with confirmed leishmaniasis were enrolled if they provided written, informed consent. Pregnant women were excluded from the study. Patients were treated with intravenous meglumine antimoniate (Glucantime; Sanofi Aventis) or generic sodium stibogluconate (Viteco), depending on drug availability, at dosages of 20 mg/kg/day for 20 (for CL) or 30 (for ML or MCL) days. Patients who failed a first course of SbV were treated with a second course of SbV with or without topical imiquimod or with conventional amphotericin B. Daily treatment was administered, under medical supervision, in outpatient clinics. All patients were asked to attend follow-up visits 1, 2, 3, 6, and 12 months after treatment. At each visit, the clinical appearance of the lesion(s) was assessed by a physician for size and the presence of signs of inflammation or scarring. The status of the lesion(s) was compared with digital pictures and drawings of the initial (pretreatment) lesion(s) and graded from M0 (no change or worsening of the lesion) to M4 (complete scarring of the lesion). Informed consent was obtained from patients or their parents or guardians. Human-experimentation guidelines of the Institute of Tropical Medicine were followed. Ethics clearance was obtained from the ethical committees of the Cayetano Heredia University, Lima, Peru, and Institute of Tropical Medicine, Antwerp, Belgium.
Definition of clinical outcomes. Initial cure (р3 months after treatment) was defined as follows: for ulcers, complete scarring of lesion(s) and disappearance of inflammatory signs; for nodular lesions, flattening and the absence of infiltration or other sign(s) of inflammation. Unresponsiveness was defined as the absence or incomplete scarring of lesion(s) and/or the persistence of inflammatory signs at 3 months after treatment or the worsening of existing lesion(s) or the appearance of new lesion(s) р3 months after treatment. Relapse was defined as the reappearance of an ulcer or nodule and/or local signs of inflammation after initial cure. Treatment failure was defined as unresponsiveness or relapse. Cure was defined as initial cure without relapse р12 months after treatment.
Parasites and in vitro culture. Parasites were isolated onto 3N blood slopes with a saline/antibiotic overlay [17] , sent to the Institute of Tropical Medicine (Antwerp, Belgium) cryopreserved in aliquots, and typed within 8 passages of isolation. Frozen stocks were sent to the London School of Hygiene and Tropical Medicine, where the parasites were passaged initially onto 3N blood slopes with M199 with a 20% heat-inactivated fetal calf serum (HIFCS) overlay and then onto M199 with 20% HIFCS alone. It was necessary to introduce the use of M199 [18] to obtain a clean bulk culture of promastigotes that would be sufficient for further evaluation. The type of medium can affect the infectivity of the parasite [19] ; however, in the present study, all isolates were exposed to exactly the same growth conditions, and the work was performed as close to the time of isolation as possible.
Parasite species identification. Leishmania species identification was performed by multilocus PCR-restriction fragment length polymorphism analysis of the gp63, Hsp70, cpb, and/or H2b genes [20] [21] [22] In vitro drug-susceptibility testing. Promastigotes were The shading patterns represent the tested phenotype: sensitive to both drugs, white; resistant to SbV and not tested with SbIII, light gray; resistant to SbV and sensitive to SbIII, dark gray; and resistant to both drugs, black.
maintained in M199 medium supplemented with 20% HIFCS at 25ЊC. All strains were tested for their in vitro sensitivity to SbV within 8 passages of isolation. Late-stage promastigotes were used to infect starch-induced murine peritoneal macrophages at a ratio of 7 promastigotes to 1 macrophage in Labtek 16-well tissue culture-well slides (VWR), in quadruplicate, and kept at 34ЊC in a 5% CO 2 /air mix. Twenty-four hours after infection, 1 slide was fixed in methanol and stained with Giemsa, for the determination of the initial level of infection. If the level of infection was 180%, the infected cultures were exposed to sodium stibogluconate (Sb[V]; GSK) over a dose range of 80, 26.6, 8.8, and 2.9 mg/mL. Stock solutions of both NaSbV and Triostam (SbIII) were formulated by dissolving the white powder in sterile PBS, followed by further dilution in complete medium. After 5 days, the percentage of infected macrophages in each well was determined by microscopic analysis [23] . The percentage of inhibition was calculated from a comparison of counts from treated and untreated cultures using sigmoidal regression analysis (xlfit version 3; Microsoft), and ED 50 values were determined. The strain L. (V.) braziliensis MHOM/BR/75/M2903, a World Health Organization reference strain that is sensitive to sodium stibogluconate and meglumine antimoniate, was included in each assay as a reference. The ratio of the ED 50 of a tested strain to the ED 50 of the reference strain (range, 4-15 mg/mL, according to the experimental series), which we termed the "activity index" (AI), was used to express the in vitro susceptibility of that tested strain and to easily compare the results obtained from different series of experiments. Sensitivity to SbIII was evaluated using the same assay. Triostam (trivalent sodium antimonyl gluconate; donated by Burroughs Wellcome) was used over a dose range of 30-1.1 mg of SbIII/mL. Comparable concentrations to SbV could not be used because of toxicity in host cells at higher concentrations. Animal experiments complied with UK government (Home Office) guidelines. Data analysis. Demographic, clinical, laboratory, treatment, and outcome data were entered into an Excel database (Excel 2003; Microsoft). All data were cross-checked with individual patient files during several data-monitoring visits by F.C. Statistical analysis was done using SPSS (version 11.0. for Windows; SPSS). For the analysis of correlations between clinical outcome and parasite sensitivity, only patients treated with antimonials who had a clear clinical outcome (cure or treatment failure) were included. Categorical variables were compared using cross-tabulations and x 2 tests, and numerical variables (parasite sensitivity) were compared using the nonparametric Mann-Whitney U test, at a critical a-level of .05.
RESULTS
In vitro susceptibility to SbV and SbIII. A total of 37 isolates was selected for in vitro susceptibility assays, all but 1 of which originated from the Amazonian forest (lowlands and high jungle), because our aim was to focus on L. All of these isolates were tested for their susceptibility to SbV. Strains with an AI of 1-2 (i.e., similar to that of the reference strain) were considered to be sensitive. Strains with an AI of у5-6 (corresponding to an ED 50 of 180 mg of SbV/mL) were considered to be resistant. With 1 exception (strain PER008, with an AI of 3), all strains that we tested belonged to 1 of these 2 categories. Sensitive and resistant parasites were ob- (2) there was a similar proportion of cures (13) and treatment failures (11) among the patients from whom they were obtained (the 2 remaining patients were lost to follow-up). Of these 37 isolates, 21 could be tested in parallel for their in vitro sensitivity to SbIII, with only 5 isolates shown to be resistant to the drug (AI of 5-6; table 1). The remaining 16 isolates showed AIs of 0-2 (0, more sensitive than the reference strain M2903). When we considered the results of SbV and SbIII together, 3 phenotypes were observed: SbV sensitive/SbIII sensitive (5S3S), SbV resistant/SbIII sensitive (5R3S), and SbV resistant/SbIII resistant (5R3R). A possible fourth combination, SbV sensitive/SbIII resistant (5S3R), was not seen in this sample. The 5R3S and 5R3R phenotypes were both seen in L. (V.) braziliensis and L. (V.) lainsoni: 5R3S parasites were more abundant in the former species (11/14 isolates), whereas 2 of 3 L. (V.) lainsoni isolates were of type 5R3R.
Geographical clustering in terms of in vitro susceptibility was not observed. SbV-resistant isolates were seen in all regions, and even the less frequently occurring 5R3R parasites were found a great distance from each other. Within the same foci, it was possible to observe different phenotypes among isolates-for example, the coexistence of 5R3R and 5R3S L. (V.) braziliensis isolates in Tambopata (eastern lowlands, close to the Bolivian border) and of 5S3S and 5R3S parasites in Junin (central high jungle).
In vitro susceptibility and treatment outcome. We compared the results of the in vitro susceptibility of the clinical isolates of L. (V.) braziliensis, L. (V.) guyanensis, and L. (V.)
lainsoni to the treatment outcome of the patients from whom they were obtained (table 2) . After the exclusion of 2 patients treated with amphotericin B, 1 patient who defaulted before the start of treatment, and 2 patients with an unclear clinical outcome, 32 patients and isolates were included in the analysis. There was no statistical correlation between SbV and SbIII in vitro sensitivity of the parasite and clinical outcome when parasite species were analyzed together or separately. Moreover, when the analysis was restricted to the 25 patients without prior treatment with antimonials who had parasites isolated and tested in vitro, we found no statistically significant association between in vitro sensitivity and clinical outcome. Two of 4 sensitive L. (V.) braziliensis isolates came from patients with treatment failure, and 11 of 19 resistant isolates of that species came from cured patients. Of the 10 5R3S and 2 5R3R isolates, 7 and 1 came, respectively, from cured patients. For patients infected with L. (V.) guyanensis and L. (V.) lainsoni, the clinical picture was somewhat different-all of them were cured with antimony treatment, but this was not dependent on the in vitro susceptibility of the infecting parasites; 5 of the patients were infected with SbV-resistant parasites.
We also analyzed the data by distinguishing L. (V.) braziliensis isolates obtained before and after antimony treatment. "Posttreatment" was considered broadly, as recruited patients either (1) without a previous history of treatment with antimonials and samples obtained after the controlled therapy of present study or (2) with a previous history of treatment and samples obtained before the controlled therapy of present study (labeled with "a" and "b" table 1). Results were similar in both categories: we observed 7 SbV-resistant isolates among the 9 posttreatment samples and 15 SbV-resistant isolates among the 17 pretreatment isolates.
DISCUSSION
Reports on antimonial resistance among clinical isolates of defined neotropical Leishmania species are scanty. Early reports described the existence of resistance to SbV in L. (V.) panamensis [13] , L. (V.) braziliensis [13] , and L. (L.) amazonensis [24] , but they were based on parasite promastigotes, which are known to be intrinsically insensitive to SbV [11, 25] . This appeared clearly when we compared ED 50 s of L. (V.) braziliensis promastigotes (220-4100 mg/mL) [13] with those of amastigotes: 4 to 180 mg/mL (present study) versus 2.6 to 1128 mg/ mL [15] . The higher ED 50 s reported by Rojas et al. [15] are likely explained by differences in the respective protocols. For the present study, macrophages were infected at a ratio of 7 parasites to 1 macrophage. Previously, it has been shown that a higher amastigote:macrophage ratio can influence the sodium stibogluconate ED 50 [26] . A lower dose range over a longer exposure period (5 days) was also used in the present study, which allowed the compound to accumulate sufficiently within infected cells [26, 27] . This demonstrates the specificity of our study and highlights the extreme care needed in comparing our data with those of previous reports.
It is known that different Leishmania species may present a different intrinsic sensitivity to antimonials. However, a more surprising result was the high frequency of SbV-resistant strains within the present sample: 28 of 35 isolates of all species and 22 of 26 L. (V.) braziliensis isolates. This contrasts with a previous report [15] in which 3 of 19 isolates were resistant before treatment and 7 of 19 were resistant after treatment failure. These differences could be due to experimental procedures, to species factors (L. [V.] panamensis was not included in our study), or to geographical variation, if hot spots of SbV resistance exist in Peru. The latter hypothesis was not supported by our results, given that all of the Peruvian SbVresistant parasites appeared to be geographically spread over the territory covered by the present study. Interestingly, we saw a totally different picture of parasite drug susceptibility after exposure to SbIII, the reduced and active component of the drug. Indeed, 16 of 21 tested isolates of Viannia subgenus and 14 of 17 L. (V.) braziliensis isolates appeared to be sensitive to SbIII. If a strain is resistant to SbV but sensitive to SbIII, can it be classed as truly resistant to antimonials? This argument may be resolved as more becomes known about the mechanism of action of antimonials and the role of various host factors. In the meantime, it might be wise to clearly define the terms of resistance at the outset of any future study or report and to make a clear distinction between real resistance caused by exposure to drug and intrinsic unresponsiveness.
A fine analysis of our results of SbV and SbIII susceptibility has already given some clues about the mechanisms leading to SbV/SbIII resistance. Indeed, the observation of 3 combinations of SbV and SbIII sensitivity phenotypes (5S3S, 5R3S, and 5R3R) and the absence in the present sample of the 5S3R combination suggests a cumulative process in which parasites would become resistant to SbV first and resistant to SbIII second. A similar observation was made in L. (L.) donovani clinical isolates from Nepal (S. Rijal, V.Y., and J.-C.D., data not shown). It is generally accepted that all pentavalent antimonials are prodrugs that require biological reduction to the trivalent form (SbIII) for antileishmanial activity, although the site (amastigote or macrophage) and mechanism of reduction remain controversial [14] . Accordingly, resistance to SbV and not to SbIII would imply a lower activation in the parasite, whereas the cumulated resistance to SbIII could be due to an additional and broader spectrum of mechanisms, such as modified influx or efflux and change of target [28] .
The high frequency of SbV resistance raises a particular concern in the generally accepted zoonotic context of leishmaniasis in the Viannia subgenus. Indeed, in this situation, humans are generally considered to be a "dead end" for transmission, and most of the parasites are in animals in which drug pressure is nonexistent. One explanation for these results may be a shift from zoonotic to anthroponotic transmission, as has been hypothesized by other researchers [15] . Several reports have suggested that some transmission cycles of neotropical Leishmania tend toward domestication [29] . However, if this were the case, geographical clustering of isolates according to their phenotype would be expected, and this was not seen in the present study. Alternatively, in a real zoonotic context, drug resistance could be acquired by many patients (secondary resistance), as has been shown in Colombia by the isolation-from the same patient-of sensitive and resistant parasites before and after treatment failure, respectively [15] . This could be due to suboptimal therapy, poor quality of the drug, or other factors. This was controlled for as much as possible in the present study. (1) Commercial brands (Glucantime) or generic sodium stibogluconate was used, and, in the latter case, each batch was shown to contain the adequate content of SbV (IDA). (2) A directly observed therapy protocol was used to ensure the correct administration of the drug. Furthermore, we encountered in L. (V.) braziliensis a high proportion (15/17) of primary SbVresistant parasites (isolated before supervised treatment from patients with no history of antimonial therapy). A last explanation compatible with zoonotic transmission could be that the observed SbV resistance does not result from previous contact with the drug but could be a secondary effect of another phenomenon. The recent demonstration of cross-resistance to antimony and nitric oxide [30] supports this possibility and should be further explored.
Another major finding was the lack of correlation between in vitro susceptibility to antimony and the clinical outcome of therapy. In a recent report on resistance to SbV in L. (V.) panamensis, a correlation of 40% was observed with treatment failure [15] , but the occurrence of resistant strains among patients responding to the treatment was not reported. Our data show that, of 13 cured patients, 11 were infected with SbVresistant L. (V.) braziliensis parasites. Obviously, our sample size could be further increased to confirm this lack of correlation, bur other explanations should be considered. The possibility that SbV susceptibility is not the correct phenotype to correlate with treatment outcome should not be excluded: indeed, of 10 cured patients for whom we had isolates with known SbV and SbIII susceptibility phenotypes, it appeared that 9 isolates were sensitive to SbIII. Nevertheless, we did not find any correlation between SbIII susceptibility and clinical outcome. The fact that many of our isolates were obtained before treatment could be a second explanation, if secondary resistance were the most frequent situation (in that case, the pretreatment sensitive isolates would obviously not correlate with treatment failure). However, as was mentioned above, most of the pretreatment isolates were already resistant in the present study. A third explanation could be that treatment failure is not due simply to the degree of parasite sensitivity to antimony but also to host factors. This is supported by previous reports that have shown that a poor response to antimonial therapy in patients infected with L. (V.) braziliensis was associated with a low lymphoproliferative response [31] . This possible explanation is further strengthened by recent trials that have demonstrated that the administration of antimony plus topical imiquimod (an innate immune-response modulator) to subjects for whom an initial course of antimony therapy failed accelerated the reepithelization of lesions and improved scar quality [32, 33] .
The present results demonstrate the need for more standardization in studies of drug resistance and its link to treatment outcome. This concerns the in vitro susceptibility assays themselves (e.g., those based on intracellular amastigotes that measure SbV and SbIII) but also the clinical aspects themselves, protocols, and, most of all, definitions. Further work should be performed in Peru, to confirm our data in a larger sample, and in other countries in the region. Ideally, they should be performed in a multicenter and multidisciplinary context, and they should certainly contain an immunological component, to consider the respective weight of parasite and human factors in the final treatment outcome.
